Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.72 |
| ▸ | GAK | O14976 | 1/20 | 0.72 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.72 |
| ▸ | ULK1 | O75385 | 1/20 | 0.72 |
| ▸ | STK10 | O94804 | 1/20 | 0.72 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.72 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.72 |
| ▸ | LATS1 | O95835 | 1/20 | 0.72 |
| ▸ | PAK4 | O96013 | 1/20 | 0.72 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.72 |
| ▸ | LCK | P06239 | 1/20 | 0.72 |
| ▸ | CDK1 | P06493 | 1/20 | 0.72 |
| ▸ | APRT | P07741 | 1/20 | 0.72 |
| ▸ | RET | P07949 | 1/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.72 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.72 |
| ▸ | NQO2 | P16083 | 1/20 | 0.72 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.72 |
| ▸ | FECH | P22830 | 1/20 | 0.72 |
| ▸ | CDK2 | P24941 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29678517 | 1.00 | IRAK4 (0.72) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL31060494 | 1.00 | IRAK4 (0.72) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL5766267 | 0.95 | IRAK4 (0.66) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL5764297 | 0.95 | IRAK4 (0.66) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL5766257 | 0.95 | IRAK4 (0.66) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL5764257 | 0.91 | IRAK4 (0.61) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL5764385 | 0.91 | IRAK4 (0.61) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL5764259 | 0.90 | IRAK4 (0.60) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL5763184 | 0.90 | IRAK4 (0.71) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL5766337 | 0.90 | IRAK4 (0.71) | IRAK4GAKRIPK2ULK1STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200163877-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2020-05-28 | — | — | US | claimed |
| US-20150224055-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC | 2015-08-13 | — | — | US | claimed |
| US-20100105031-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | ESAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | claimed |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | claimed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| US-7019147-B1 | Benzimidazole derivatives useful as antiproliferative agents | PFIZER INC. (US) | 2006-03-28 | — | — | US | claimed |
| EP-1235825-B1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PROD INC (US) | 2006-01-25 | — | — | EP | claimed |
| EP-1235825-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | claimed |
| WO-2001040217-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | claimed |
| US-20230357714-A1 | STEM CELL CULTURE SYSTEMS FOR COLUMNAR EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357714-A1 | STEM CELL CULTURE SYSTEMS FOR COLUMNAR EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-11-09 | — | — | US | disclosed |
| US-11725185-B2 | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| US-11725185-B2 | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| US-11712419-B2 | Liposome formulations | OPKO PHARMACEUTICALS, LLC (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2006038111-A1 | BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-7019147-B1 | Benzimidazole derivatives useful as antiproliferative agents | PFIZER INC. (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1235825-B1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PROD INC (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1235825-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001040217-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | VEGFA, FLT4, MKI67 | IRAK4 3325/4885GAK 1065/4885RIPK2 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.